Generic Name:
zanubrutinib
Project Status:
Received
Therapeutic Area:
Chronic lymphocytic leukemia /small lymphocytic lymphoma.
Manufacturer:
BeiGene Canada ULC
Call for patient/clinician input open:
Brand Name:
Brukinsa
Project Line:
Reimbursement Review
Project Number:
PC0310-000
Call for patient/clinician input closed:
Tumour Type:
Leukemia
NOC Status at Filing:
Pre NOC
Details
Manufacturer Requested Reimbursement Criteria1:
For the treatment of
adult patients with chronic lymphocytic leukemia /small lymphocytic lymphoma
(CLL/SLL).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of
adult patients with chronic lymphocytic leukemia /small lymphocytic lymphoma
(CLL/SLL).
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.